SARS: systematic review of treatment effects

Lauren J Stockman, Richard Bellamy, Paul Garner, Lauren J Stockman, Richard Bellamy, Paul Garner

Abstract

Background: The SARS outbreak of 2002-2003 presented clinicians with a new, life-threatening disease for which they had no experience in treating and no research on the effectiveness of treatment options. The World Health Organization (WHO) expert panel on SARS treatment requested a systematic review and comprehensive summary of treatments used for SARS-infected patients in order to guide future treatment and identify priorities for research.

Methods and findings: In response to the WHO request we conducted a systematic review of the published literature on ribavirin, corticosteroids, lopinavir and ritonavir (LPV/r), type I interferon (IFN), intravenous immunoglobulin (IVIG), and SARS convalescent plasma from both in vitro studies and in SARS patients. We also searched for clinical trial evidence of treatment for acute respiratory distress syndrome. Sources of data were the literature databases MEDLINE, EMBASE, BIOSIS, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to February 2005. Data from publications were extracted and evidence within studies was classified using predefined criteria. In total, 54 SARS treatment studies, 15 in vitro studies, and three acute respiratory distress syndrome studies met our inclusion criteria. Within in vitro studies, ribavirin, lopinavir, and type I IFN showed inhibition of SARS-CoV in tissue culture. In SARS-infected patient reports on ribavirin, 26 studies were classified as inconclusive, and four showed possible harm. Seven studies of convalescent plasma or IVIG, three of IFN type I, and two of LPV/r were inconclusive. In 29 studies of steroid use, 25 were inconclusive and four were classified as causing possible harm.

Conclusions: Despite an extensive literature reporting on SARS treatments, it was not possible to determine whether treatments benefited patients during the SARS outbreak. Some may have been harmful. Clinical trials should be designed to validate a standard protocol for dosage and timing, and to accrue data in real time during future outbreaks to monitor specific adverse effects and help inform treatment.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Process of Study Exclusion for…
Figure 1. Process of Study Exclusion for Each Objective Category

References

    1. World Health Organization. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. 2004. Available: . Accessed 26 July 2005.
    1. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348:1953–1966.
    1. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361:1319–1325.
    1. Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348:1967–1976.
    1. Peiris JS, Yuen KY, Osterhaus AD, Stohr K. The severe acute respiratory syndrome. N Engl J Med. 2003;2003:2431–2441.
    1. Leung GM, Hedley AJ, Ho LM, Chau P, Wong IO, et al. The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: An analysis of all 1755 patients. Ann Intern Med. 2004;141:662–673.
    1. Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, et al. Critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290:367–373.
    1. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 290:374–380.
    1. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995–2005.
    1. Lee N, Hui D, Wu A, Chan P, Cameron P, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348:1986–1994.
    1. World Health Organization. Future clinical trials for SARS, Informal meeting and workshop. Draft Report. Geneva: World Health Organization; 2003.
    1. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J., Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326:905–908.
    1. Chen F, Chan KH, Jiang Y, Kao RY, Lu HT, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31:69–75.
    1. Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis. 2003;37:1139–1142.
    1. Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809.
    1. Sung JJ, Wu A, Joynt GM, Yuen KY, Lee N, et al. Severe acute respiratory syndrome: Report of treatment and outcome after a major outbreak. Thorax. 2004;59:414–420.
    1. Wong WM, Ho JC, Hung IF, Ng W, Lam YM, et al. Temporal patterns of hepatic dysfunction and disease severity in patients with SARS (4) JAMA. 2003;290:2663–2665.
    1. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318:719–725.
    1. Chan KS, Lai ST, Chu CM, Tsui E, Tam CY, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: A multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9:399–406.
    1. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, et al. Role of lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings. Thorax. 2004;59:252–256.
    1. Lee N, Allen Chan KC, Hui DS, Ng EK, Wu A, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31:304–309.
    1. Lee DTS, Wing YK, Leung HCM, Sung JJY, Ng YK, et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: A case-control study. Clin Infect Dis. 2004;39:1247–1249.
    1. Xiao JZ, Ma L, Gao J, Yang ZJ, Xing XY, et al. [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: The impact of high dosage and duration of methylprednisolone therapy] Zhonghua Nei Ke Za Zhi. 2004;43:179–182.
    1. Li YM, Wang SX, Gao HS, Wang JG, Wei CS, et al. [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence] Zhonghua Yi Xue Za Zhi. 2004;84:1348–1353.
    1. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med. 1987;317:1565–1570.
    1. Weigelt JA, Norcross JF, Borman KR, Snyder WH., 3rd Early steroid therapy for respiratory failure. Arch Surg. 1985;120:536–540.
    1. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA. 1998;280:159–165.
    1. Scagnolari C, Vicenzi E, Bellomi F, Stillitano MG, Pinna D, Poli G, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther. 2004;9:1003–1011.
    1. Sainz B, Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) Virology. 2004;329:11–17.
    1. Wu W, Wang JF, Liu PM, Chen WX, Yin SM, et al. [Clinical features of 96 patients with severe acute respiratory syndrome from a hospital outbreak] Zhonghua Nei Ke Za Zhi. 2003;42:453–457.
    1. Li ZZ, Shen KL, Wei XM, Wang HL, Lu J, et al. [Clinical analysis of pediatric SARS cases in Beijing] Zhonghua Er Ke Za Zhi. 2003;41:574–577.
    1. Hwang DM, Chamberlain DW, Poutanen SM, Low DE, Asa SL, et al. Pulmonary pathology of severe acute respiratory syndrome in Toronto. Mod Pathol. 2005;18:1–10.
    1. Wang H, Ding Y, Li X, Yang L, Zhang W, et al. Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. N Engl J Med. 2003;349:507–508.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다